Objective  To mine and analyze adverse drug events (ADEs) signals in minors using recombinant human growth hormone (rhGH), and to provide reference for clinically safe use of drugs.

Methods  Based on the the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database, the data of ADE reports related to rhGH from the third quarter of 2014 to the second quarter of 2024 were retrieved. The ADE reports were standardized and categorized using the Medical Dictionary for Regulatory Activities (MedDRA). The reporting odds ratio (ROR) method and Bayesian confidence propagation neural network (BCPNN) method were employed to mine and analyze ADE signals between rhGH and individuals under 18 years of age.

Results  A total of 33,642 ADE reports related to the use of rhGH in minors were retrieved. After excluding signals unrelated to ADEs (product issues, social issues, etc.), 358 ADE signals were ultimately identified, involving 21 system organ lasses (SOCs). The most frequently reported ADEs were general disorders and administration site reactions (3,621 cases), as well as various laboratory test abnormalities (3,259 cases). Notably, ADE signals related to cardiovascular system tests, psychiatric disorders, and reproductive system and breast disorders, such as decreased serum creatinine, elevated alkaline phosphatase, reduced red blood cell distribution width, crying, aggression, and hypogonadism, were not documented in the drug package insert.

Conclusion  When administering rhGH to minors, in addition to monitoring common ADEs such as changes in blood glucose levels and scoliosis, attention should also be given to potential ADEs, including alterations in hematological parameters, psychiatric issues, and reproductive system and breast disorders, to ensure medication safety.

1.Ranke MB, Wit JM. Growth hormone - past, present and future[J]. Nat Rev Endocrinol, 2018, 14(5): 285-300. DOI: 10.1038/nrendo.2018.22.

2.中华医学会儿科学分会内分泌遗传代谢学组. 中国儿童生长激素缺乏症诊治指南[J]. 中华儿科杂志, 2024, 62(1): 5-11. [The Subspecialty Group of Endocrinology, Hereditary and Metabolic Diseases, the Society of Pediatrics, Chinese Medical Association. Chinese guidelines for the diagnosis and treatment of pediatric growth hormone deficiency[J]. Chinese Journal of Pediatrics, 2024, 62(1): 5-11.] DOI: 10.3760/cma.j.cn112140-20230914-00183.

3.Bamba V, Kanakatti Shankar R. Approach to the patient: safety of growth hormone replacement in children and adolescents[J]. J Clin Endocrinol Metab, 2022, 107(3): 847-861. DOI: 10.1210/clinem/dgab746.

4.Huh K, Nah WH, Xu Y, et al. Effects of recombinant human growth hormone on the onset of puberty, leydig cell differentiation, spermatogenesis and hypothalamic KISS1 expression in immature male rats[J]. World J Mens Health, 2021, 39(2): 381-388. DOI: 10.5534/wjmh.200152.

5.Patel NM, Stottlemyer BA, Gray MP, et al. A pharmacovigilance study of adverse drug reactions reported for cardiovascular disease medications approved between 2012 and 2017 in the United States Food and Drug Administration adverse event reporting system (FAERS) database[J]. Cardiovasc Drugs Ther, 2022, 36(2): 309-322. DOI: 10.1007/s10557-021-07157-3.

6.魏安华, 曾露, 王璐, 等. 基于FAERS数据库的替诺福韦二吡呋酯和丙酚替诺福韦不良事件分析及肾脏安全性比较[J]. 药物流行病学杂志, 2023, 32(12): 1362-1370. [Wei AH, Zeng L, Wang L, et al. Comparison of adverse events and renal safety between tenofovir disoproxil and tenofovir propofol based on FAERS database[J]. Chinese Journal of Pharmacoepidemiology, 2023, 32(12): 1362-1370.] DOI: 10.19960/j.issn.1005-0698.202312006.

7.Shu YM, He XC, Liu YX, et al. A real-world disproportionality analysis of olaparib: data mining of the public version of FDA adverse event reporting system[J]. Clin Epidemiol, 2022, 14: 789-802. DOI: 10.2147/CLEP.S365513.

8.陈欢, 文朋. 基于 BCPNN 法对来迪派韦/索磷布韦药物警戒信号的挖掘[J]. 中国医院药学杂志, 2021, 41(16): 1631-1636. [Chen H, Wen P. Pharmacovigilance signal detection of ledipasvir/sofosbuvir based upon Bayesian confidence propagation neural network[J]. Chinese Journal of Hospital Pharmacy, 2021, 41(16): 1631-1636.] DOI: 10.13286/j.1001-5213.2021.16.07.

9.Fleseriu M, Christ-Crain M, Langlois F, et al. Hypopituitarism[J]. Lancet, 2024, 403(10444): 2632-2648. DOI: 10.1016/S0140-6736(24)00342-8.

10.Boguszewski MCS. Growth hormone deficiency and replacement in children[J]. Rev Endocr Metab Disord, 2021, 22(1): 101-108. DOI: 10.1007/s11154-020-09604-2.

11.Sävendahl L, Maes M, Albertsson-Wikland K, et al. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, the Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study[J]. J Clin Endocrinol Metab, 2012, 97(2): E213-E217. DOI: 10.1210/jc.2011-2882.

12.Carel JC, Ecosse E, Landier F, et al. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study[J]. J Clin Endocrinol Metab, 2012, 97(2): 416-425. https://doi.org/10.1210/jc.2011-1995.

13.Sävendahl L, Cooke R, Tidblad A, et al. Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study[J]. Lancet Diabetes Endocrinol, 2020, 8(8): 683-692. DOI: 10.1016/S2213-8587(20)30163-7.

14.Tidblad A, Bottai M, Kieler H, et al. Association of childhood growth hormone treatment with long-term cardiovascular morbidity[J]. JAMA Pediatr, 2021, 175(2): e205199. DOI: 10.1001/jamapediatrics.2020.5199.

15.Rogol AD. Safety of rhGH, early vs late: the hare seems fine, but what about the tortoise?[J]. J Clin Endocrinol Metab, 2021, 106(6): e2450-e2451. DOI: 10.1210/clinem/dgab116.

16.Chang CW, Sung YW, Hsueh YW, et al. Growth hormone in fertility and infertility: mechanisms of action and clinical applications[J]. Front Endocrinol (Lausanne), 2022, 13: 1040503.DOI: 10.3389/fendo.2022.1040503.

17.Pan P, Huang X. The clinical application of growth hormone and its biological and molecular mechanisms in assisted reproduction[J]. Int J Mol Sci, 2022, 23(18): 10768. DOI: 10.3390/ijms231810768.

18.Andreassen M, Frystyk J, Faber J, et al. Growth hormone (GH) activity is associated with increased serum oestradiol and reduced anti-Müllerian hormone in healthy male volunteers treated with GH and a GH antagonist[J]. Andrology, 2013, 1(4): 595-601. DOI: 10.1111/j.2047-2927.2013.00096.x.

19.Bertelloni S, Baroncelli GI, Viacava P, et al. Can growth hormone treatment in boys without growth hormone deficiency impair testicular function?[J]. J Pediatr, 1999, 135(3): 367-370. DOI: 10.1016/s0022-3476(99)70136-8.

20.Albrecht A, Penger T, Marx M, et al. Short-term adverse effects of testosterone used for priming in prepubertal boys before growth hormone stimulation test[J]. J Pediatr Endocrinol Metab, 2018, 31: 21-24. DOI: 10.1515/jpem-2017-0280.

21.Radicioni AF, Paris E, De Marco E, et al. Testicular function in boys previously treated with recombinant-human growth hormone for non-growth hormone-deficient short stature[J]. J Endocrinol Invest, 2007, 30(11): 931-936. DOI: 10.1007/BF03349240.

22.Christiansen LI, Holmqvist B, Pan X, et al. Insulin-like growth factor-1 supplementation promotes brain maturation in preterm pigs[J]. eNeuro, 2023, 10(4): ENEURO.0430-22.2023. DOI: 10.1523/ENEURO.0430-22.2023.

23.Merino E, Raya-Salom D, Teruel-Martí V, et al. Effects of acute stress on the oscillatory activity of the hippocampus-amygdala-prefrontal cortex network[J]. Neuroscience, 2021, 476: 72-89. DOI: 10.1016/j.neuroscience.2021.09.009.

24.章萌, 聂晓璐, 刘佐相, 等. 中美两国2009—2020年不同人群ADR/ADE报告分析及对中国药物警戒工作的启示[J]. 药物流行病学杂志, 2022, 31(12): 808-814. [Zhang M, Nie XL, Liu ZX, et al. Analysis of adverse drug reactions or adverse drug events of different populations in China and the United States from 2009 to 2020 and implications for pharmacovigilance in China[J]. Chinese Journal of Pharmacoepidemiology, 2022, 31(12): 808-814.] DOI: 10.19960/j.cnki.issn1005-0698.2022.12.005.